Pivot Pharma Licenses Thrudermic Transdermal Nanotechnology and Expands Scientific Advisory Board - Seite 2
Dr. Patrick Frankham, Pivot's CEO, comments, "Thrudermic is Pivot's third innovative drug delivery technology and we are thrilled that Dr. Borovsky and Dr. Lurya have agreed to collaborate with us to develop and commercialize therapeutic pharmaceuticals and nutraceuticals to meet the growing demand for cannabinoid based products. Pivot is well positioned to demonstrate the value of these as therapeutics. Currently the marketplace is inundated with sub-par products developed using inert oils and in vehicles that don't deliver meaningful dosing. To date, smoking is the main choice for route of administration since there are no good formulations available."
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is an emerging biopharmaceutical company engaged in the
development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot's wholly-owned medical cannabis products division,
Pivot Green Stream Health Solutions Inc. ("PGS" or Pivot Green Stream), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has
acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical); Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for
the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS' initial product development candidates will include topical treatments
for women's sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. PGS will seek to register these as Natural Health Products
(NHP) for consumers. Products following the NHP pathway have shorter development cycles and can generate revenue faster than traditional pharmaceuticals. For more information please visit
www.PivotPharma.com
Cautionary Statement
Except for historical information contained herein, the matters set forth above may be forward-looking statements that
involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate,
believe, estimate, expect, intend, and similar expressions, as they relate to Pivot, ACI Foods, or Pivot Green Stream, or its
management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available
to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the level of business and consumer spending,
the amount of sales of Pivot's products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with
Pivot's expansion efforts, economic conditions in the industry, and the financial strength of Pivot's customers and suppliers. Pivot does not undertake any obligation to update such forward-looking
statements. Investors are also directed to consider all other risks and uncertainties.
Lesen Sie auch
Contact:
Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Email Contact
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Email Contact